Z-338

DRUG7 trials

Sponsors

Zeria Pharmaceutical, Astellas Pharma Inc

Conditions

DyspepsiaFunctioanl DyspepsiaFunctional DyspepsiaHealthy

Phase 1

Effect of Food Intake on Pharmacokinetic Profiles of Z-338

CompletedNCT00920998

Astellas Pharma IncHealthy

Start: 2009-03-31End: 2009-06-30Updated: 2009-07-20

Phase 2

The Effects of Z-338 in Subjects With and Without Functional Dyspepsia

CompletedNCT00298194

Zeria PharmaceuticalDyspepsia

Start: 2006-02-28Target: 52Updated: 2009-01-14

To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

CompletedNCT00323817

Zeria PharmaceuticalFunctional Dyspepsia

Start: 2006-04-30End: 2009-10-31Target: 282Updated: 2015-05-28

To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia

CompletedNCT00333372

Zeria PharmaceuticalFunctional Dyspepsia

Start: 2006-04-30Target: 440Updated: 2009-01-14

The Effect of Z-338 in Subjects With Functional Dyspepsia

CompletedNCT00458328

Zeria PharmaceuticalFunctioanl Dyspepsia

Start: 2007-04-30End: 2010-07-31Target: 40Updated: 2010-11-23

Phase 3

To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia

CompletedNCT00761358

Zeria PharmaceuticalFunctional Dyspepsia

Start: 2008-09-30End: 2010-08-31Target: 820Updated: 2010-11-23

Phase III, Long-term, Open-label Safety Study of Z-338

CompletedNCT01973790

Zeria PharmaceuticalDyspepsia

Start: 2014-03-31End: 2017-04-30Updated: 2017-06-28

Related Papers

Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.

2018-01-0829 citations

A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.

2011-12-09168 citations